医学
致盲
甲状腺
食品药品监督管理局
发病机制
甲状腺疾病
眼病
疾病
眼科
生物信息学
内科学
药理学
临床试验
生物
作者
Raymond S. Douglas,George J. Kahaly,Amy Patel,Saba Sile,Elizabeth H. Thompson,Renee Perdok,James C. Fleming,Brian Fowler,Claudio Marcocci,Michele Marinò,Alessandro Antonelli,Roger A. Dailey,Gerald J. Harris,Anja Eckstein,Jade S. Schiffman,Rosa A. Tang,Christine C. Nelson,Mario Salvi,Sara T. Wester,Jeffrey W. Sherman
标识
DOI：10.1056/nejmoa1910434
摘要
Among patients with active thyroid eye disease, teprotumumab resulted in better outcomes with respect to proptosis, Clinical Activity Score, diplopia, and quality of life than placebo; serious adverse events were uncommon. (Funded by Horizon Therapeutics; OPTIC ClinicalTrials.gov number, NCT03298867, and EudraCT number, 2017-002763-18.).
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
大力的灵雁
Criminology34
mark2026
GingerF
鸟兽兽
三四郎
eric888
YifanWang
无极微光
OsamaKareem
好朋友小潘
张欢馨
xiaolizi
yorha3h
脆蜜金桔
QZR
Joyce
殷勤的紫槐
Albert_Z
arniu2008
皖公网安备34019202002308
